Sagimet Biosciences: The U.S. Acne Trial Is A Replication Exercise, Not A Discovery Bet
Sagimet Biosciences' denifanstat enters a fully funded U.S. acne registration trial after Phase 3 results, with SGMT trading below cash and…
Equity Eagle NASDAQ
Sagimet Biosciences Inc.
SGMT
1 story
$695M Market cap · 2026-10-20
Equity Eagle 